Related Experiment Video
Updated: May 11, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
Simultaneous identification of multiple driver pathways in cancer
Mark D M Leiserson1, Dima Blokh, Roded Sharan
1Department of Computer Science and Center for Computational Molecular Biology, Brown University, Providence, RI, USA.
Abstract:
Distinguishing the somatic mutations responsible for cancer (driver mutations) from random, passenger mutations is a key challenge in cancer genomics. Driver mutations generally target cellular signaling and regulatory pathways consisting of multiple genes. This heterogeneity complicates the identification of driver mutations by their recurrence across samples, as different combinations of mutations in driver pathways are observed in different samples. We introduce the Multi-Dendrix algorithm for the simultaneous identification of multiple driver pathways de novo in somatic mutation data from a cohort of cancer samples. The algorithm relies on two combinatorial properties of mutations in a driver pathway: high coverage and mutual exclusivity. We derive an integer linear program that finds set of mutations exhibiting these properties. We apply Multi-Dendrix to somatic mutations from glioblastoma, breast cancer, and lung cancer samples. Multi-Dendrix identifies sets of mutations in genes that overlap with known pathways - including Rb, p53, PI(3)K, and cell cycle pathways - and also novel sets of mutually exclusive mutations, including mutations in several transcription factors or other genes involved in transcriptional regulation. These sets are discovered directly from mutation data with no prior knowledge of pathways or gene interactions. We show that Multi-Dendrix outperforms other algorithms for identifying combinations of mutations and is also orders of magnitude faster on genome-scale data. Software available at: http://compbio.cs.brown.edu/software.
Insights
Identifying cancer driver mutations is crucial. Multi-Dendrix algorithm efficiently finds multiple cancer driver pathways by analyzing mutation patterns, outperforming existing methods in speed and accuracy.
Area of Science:
- Genomics
- Bioinformatics
- Computational Biology
Background:
- Distinguishing cancer driver mutations from passenger mutations is a significant challenge in cancer genomics.
- Driver mutations often affect multiple genes within cellular signaling and regulatory pathways, leading to heterogeneity that complicates identification.
- Recurrence-based methods struggle with identifying driver pathways due to varied mutation combinations across samples.
Purpose of the Study:
- To introduce the Multi-Dendrix algorithm for de novo identification of multiple driver pathways from somatic mutation data.
- To address the challenge of identifying driver mutations in heterogeneous cancer genomics data.
- To provide a computational tool for discovering novel cancer-associated gene sets.
Main Methods:
- Developed the Multi-Dendrix algorithm, leveraging high coverage and mutual exclusivity of mutations within driver pathways.
- Formulated an integer linear program to identify sets of mutations exhibiting these combinatorial properties.
- Applied Multi-Dendrix to somatic mutation data from glioblastoma, breast cancer, and lung cancer cohorts.
Main Results:
- Multi-Dendrix successfully identified known cancer pathways (e.g., Rb, p53, PI(3)K, cell cycle) and novel sets of mutually exclusive mutations.
- Discovered new sets of mutations in transcription factors and genes involved in transcriptional regulation.
- Demonstrated superior performance over existing algorithms in identifying mutation combinations and significantly improved computational speed.
Conclusions:
- Multi-Dendrix enables the discovery of multiple driver pathways directly from mutation data without prior pathway knowledge.
- The algorithm offers a robust and efficient approach for cancer genomics research.
- Identified novel potential driver pathways, advancing our understanding of cancer biology.
More Related Videos
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

